

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 October 2002 (03.10.2002)

PCT

(10) International Publication Number
WO 02/076451 A1

(51) International Patent Classification⁷: **A61K 31/4015**,
A61P 31/04, 31/12, 33/00, 31/16, 31/18, 35/00

(74) Agent: NORRIS, Allen; UCB, S.A. - Intellectual Property
Department, Allée de la Recherche 60, B-1070 Brussels
(BE).

(21) International Application Number: PCT/EP02/03106

(22) International Filing Date: 20 March 2002 (20.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
01107140.4 22 March 2001 (22.03.2001) EP

(71) Applicant (for all designated States except US): UCB, S.A.
[BE/BE]; Allée de la Recherche 60, B-1070 Brussels (BE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PEUVOT, Jacques
[BE/BE]; Avenue du Bosquet 34, B-1470 Bousval (BE).
BRASSEUR, Robert [BE/BE]; Voies des Gérons, 250,
B-5351 Haillot (BE). DELEERS, Michel [BE/BE]; Square
des Braves 12, B-1630 Linkebeek (BE). PONTES, Fausto,
A. [PT/PT]; Centro Hospitalar de Coimbra, 3041-801 S.
Martinho do bispo, Coimbra (PT). RUYSSCHAERT,
Jean-Marie [BE/BE]; 7, avenue des Perce-Neige, B-1640
Rhode St. Genèse (BE).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/076451 A1

(54) Title: USE OF CERTAIN SUBSTITUTED PYRROLIDONES SUCH AS PIRACETAM IN THE TREATMENT OF VIRAL AND OTHER DISEASES

(57) Abstract: The invention concerns the use of certain pyrrolidone derivatives for the preparation of medicaments for the prevention and treatment of diseases caused by the tilted insertion of fusion peptides into cell membranes. It is particularly suitable for the prevention and treatment of viral diseases.

USE OF CERTAIN SUBSTITUTED PYRROLIDONES SUCH AS PIRACETAM IN THE TREATMENT OF VIRAL AND OTHER DISEASES

The present invention concerns the use of certain substituted pyrrolidones, their pharmaceutically acceptable salts and their isomers in the prevention and treatment of viral and other diseases resulting from tilted insertion of fusion proteins into the membranes of cells and for the preparation of medicaments intended for the prevention and treatment of such diseases.

Cellular life exists because of a segregation between the interior of the cell and its external environment. This separation is achieved by a biological membrane which is essentially formed of lipids and proteins. The lipid composition and the protein composition vary considerably from one cellular type to another. However, in all cases, the membrane of the cell is a barrier which prevents prolonged contact between the intracellular domain and the extracellular liquid.

Nevertheless a number of phenomena are involved in the re-organisation of membrane structure, for example to allow the fusion and passage of proteins across the membrane. Membrane fusion reactions occur continuously in all eukaryotic cells, and are involved in different processes such as endocytosis, exocytosis, and enveloped virus infections which require one or more critical membrane fusion reactions.

In particular, the entry into the cell of many infectious agents such as viruses, parasites and bacterial pathogens proceeds *via* a mechanism of fusion and passage of proteins across the membrane.

A key feature in viral and cellular fusion phenomena is the involvement of specific fusion proteins. Among the few well-characterized fusion proteins are the viral spike glycoproteins which are responsible for penetration of enveloped viruses into their host cells leading to infection.

These proteins possess in their sequence a "fusion peptide", a short segment, typically no more than 40 especially up to 20 amino acids long, of relatively hydrophobic residues, commonly found in a membrane-anchored polypeptide chain.

Conformational analysis of the fusion protein of the virus causing Newcastle disease has made possible an understanding of its mode of action (Le *et al*, 1988 Virus Genes 1 (4), 333-350). Classical sequence analysis methods have revealed that

CONFIRMATION COPY

the N-terminal portion of the fusion protein is strongly hydrophobic and molecular modeling has shown that this peptide inserts itself in oblique or tilted fashion in the lipids.

5 In recent years, candidate virus-cell fusion proteins involved in different fusion processes have been identified, and evidence concerning the presence of a fusion peptide has been obtained for some of these proteins (Muga *et al.*, 1994 Biochemistry 33, 3201-3209; Hernandez *et al.*, 1996 Annu. Rev. Cell Dev. Biol. 12, 627-661; Wolfsberg and White, 1996 Dev. Biol., 180, 389-40; Martin and Ruyschaert, 1997
10 FEBS Lett 405, 351-355; Schanck *et al.*, 1998 J.Chim Phys. 95, 467-473).

Other viral fusion peptides, including that of SIV, have been analysed by molecular modeling and were shown to possess the property of inserting themselves obliquely as α -helices within the lipid layers

15

Candidate fusion proteins have also been evidenced by conformational analysis of the fusion proteins of parasites.

20 For malaria, affecting about 280 millions of people worldwide, the CS (circumsporozoite) protein located at the surface of the sporozoite membrane has been recognized to be responsible for the binding and the penetration of the malarial parasite in hepatocytes (Cerami *et al.* 1992 Cell 70, 1021-1033; Ménard *et al.*, 1997 Nature 385, 336-340).

25 Molecular modeling has identified an amino acid fragment in this protein exhibiting the properties of a potential fusion peptide that inserts obliquely with a tilted insertion angle of 50° into the lipid layers (Peuvot *et al.*, 1999, J. Theor.Biol. 198, 173-181).

30 When bacterial infections are considered, an important step in the understanding of infective mechanisms by the tuberculosis bacillus was made in 1993 (Arruda *et al.*, 1993 Science 261, 1454-1457). *Mycobacterium tuberculosis* first infects macrophages. A DNA fragment was isolated that allows the bacillus to enter the macrophage and to survive in human cells. This fragment was introduced into the
35 genome of *E.coli* which was then able to penetrate inside macrophages and to resist destruction. This DNA fragment contains two sub-units responsible, respectively, for penetration and survival in the cell.

The occurrence of tilted peptides has been discovered in two neurodegenerative diseases. The discovery of these tilted fragments in proteins involved in these neurodegenerative diseases originally surprised researchers, since those peptides were not known to be involved in membrane fusion (Brasseur *et al.*, 1997 TIBS 22, 167-171).

Alzheimer's disease (AD) is a progressive dementia affecting about 5 – 10 % of people over the age of 65 (Ebly *et al.*, 1994; Neurology 44, 1593-1600). AD is characterized pathologically by the deposition of extracellular amyloid, containing the β -amyloid protein ($A\beta$) which is derived from the β -amyloid protein precursor (APP) (Kang *et al.*, 1987 Nature 325, 733-736; Glenner and Whong, 1994 Biochem. Biophys. Res. Commun. 120, 885-890; Masters *et al.*, 1985 Proc. Natl. Acad. Sci. USA 82, 4245-4249).

Computer modeling of the β -amyloid peptide showed that the C-terminal domain of $A\beta$ (e.g. 29-40 or 29-42 peptide) has properties similar to those of the fusion peptide of viral proteins (Horth *et al.*, 1991 EMBO J. 10, 2747-2755).

The 29-42 tilted peptide inserts into the membrane with an insertion angle of 50° and the 29-40 peptide with an insertion angle of 40°. $A\beta$ -(29-42) peptide is the more potent fusogenic peptide and its fusogenic properties are closest to those of the SIV fusion peptide, because it can insert deeper into the lipid bilayer than the $A\beta$ -(29-40) peptide (Pillot *et al.*, 1996 J.Biol.Chem. 271, 28757-28765).

Several proteins involved in other neurodegenerative diseases were also analyzed and all have tilted peptides.

Therefore, whatever the particular mechanism may be, tilted peptides could play a role in neurodegenerative diseases.

Brasseur, 1991 (J. Biol. Chem. 266, 16120-16127), Peuvot *et al.* 1999 (J. Theor.Biol. 198, 173-181) and Brasseur *et al.* 2000 (Mol. Membrane Biol. 17(1), 31-40) provide an overview of the above-mentioned studies and others and include examples of viral fusion proteins and methods for their detection.

Thus, tilted peptides are found in many fragments of proteins previously described to experimentally induce fusion and it appears that the tilted insertion of fusion peptides plays a crucial role in the development of many different diseases including viral, parasital, bacterial, cancerous and neurodegenerative diseases.

5

Therefore, a means of interfering with these peptide functions involving tilted insertion of fusion peptides would present considerable therapeutic interest in creating for example antiviral, antiparasital, antibacterial, anticancerous, or antineurodegenerative agents. It is a purpose of the present invention to provide such a means.

10


A study using the complementary combination of an experimental tool, the ^{31}P NMR, and a theoretical method, conformational analysis, has described the molecular effect of the substituted pyrrolidone, piracetam (Peuvot *et al.*, 1995 Biochem. Pharmacol 50-8, 1129-1134). An *in vitro* test has also shown the ability of piracetam to stop the replication of herpes simplex virus 1 (HSV1) in Vero cells culture (Y.M. Centifanto, 1992 Antiviral Res. 17, suppl. 1, 114).

15

It has now surprisingly been found that certain substituted pyrrolidones are able to prevent or inhibit destabilisation induced by the tilted insertion of fusion peptides into the membranes of cells.

20

The present invention therefore concerns the use of a compound of formula I, in racemic or isomeric form, or a pharmaceutically acceptable salt thereof,



25

wherein

- R represents hydrogen or hydroxy;
- R^1 and R^2 represent independently hydrogen or an alkyl group of 1-4 carbon atoms; and

- R³ and R⁴ represent independently hydrogen, an alkyl group of 1-4 carbon atoms or $-(CH_2)_n - NR^5R^6$ wherein n is 1, 2 or 3 and R⁵ and R⁶ represent independently hydrogen or an alkyl group of 1-4 carbon atoms;
for the preparation of a medicament to prevent and treat diseases resulting from or
5 mediated by the tilted insertion of fusion peptides into cell membranes.

The compound of formula I wherein R, R¹, R², R³ and R⁴ are hydrogen, 2-oxo-pyrrolidineacetamide, has the generic name PIRACETAM has been described in UK Patents Nos. 1,039,113 and 1,309,692 and is useful in the treatment of motion
10 sickness, hyperkinesia and epilepsy.

UK Patent No. 1,309,692 also describes the compound of formula I wherein R¹ is ethyl, and R, R², R³ and R⁴ are hydrogen, in racemic form, α -ethyl-2-oxo-1-pyrrolidineacetamide, also known as ETIRACETAM.
15

The compound of formula I wherein R¹ is ethyl, and R, R², R³ and R⁴ are hydrogen, in levorotatory form, (S)- α -ethyl-2-oxo-1-pyrrolidineacetamide, also known as LEVETIRACETAM, has been described in EP 0 162 036 B1 as a drug useful in preventing hypoxia and ischemia.
20

LEVETIRACETAM is also an efficacious therapeutic agent for the treatment of epilepsy (Gower *et al.*, 1992 Eur. J. Pharmacol. 222, 2-3).

The compound of formula I wherein R¹ is an ethyl, and R, R², R³ and R⁴ are
25 hydrogen, in dextrorotatory form, (R)-(-) α -ethyl-2-oxo-1-pyrrolidineacetamide, has been described in EP 0 165 919 B1 as a drug useful to treat cerebral insufficiencies and memory disorders.

The compound of formula I wherein R, R¹, R² and R³ are hydrogen and R⁴ is
30 diisopropylaminoethyl, N-[2-(diisopropylamino)ethyl]-2-oxo-1-pyrrolidineacetamide, also known as PRAMIRACETAM, has been described in US Patent No. 4,145,347 along with its use as a cognition activator and in treating induced amnesia and learning disabilities.

35 The compound of formula I wherein R is hydroxy and R¹, R², R³ and R⁴ are hydrogen, 4-hydroxy-2-oxo-1-pyrrolidineacetamide, also known as OXIRACETAM, has been described in US Patent No. 4,118,396 along with its CNS activity.


The remaining compounds of formula I are new and also form part of the invention.

5 The compounds for use in accordance with the present invention are able to inhibit the tilted insertion of fusion peptides into the membranes of the cells. This makes them particularly useful to treat or preferably prevent diseases resulting from or mediated by the tilted insertion of fusion peptides into cell membranes.

10

The invention therefore further concerns a method of treating and preventing diseases resulting from or mediated by the tilted insertion of fusion peptides in a patient which comprises administering to a patient needing such treatment and prevention an effective amount of a compound of formula I, in racemic or isomeric

15 form, or a pharmaceutically acceptable salt thereof;



wherein

- R represents hydrogen or hydroxy;
- 20 - R^1 and R^2 represent independently hydrogen or an alkyl group of 1-4 carbon atoms; and
- R^3 and R^4 represent independently hydrogen, an alkyl group of 1-4 carbon atoms or $-(CH_2)_n - NR^5R^6$ wherein n is 1, 2 or 3 and R^5 and R^6 represent independently hydrogen or an alkyl group of 1-4 carbon atoms.

25

As discussed herein a wide variety of diseases appear to be mediated by the tilted insertion of fusion proteins into the membranes of cells. Non-limiting examples include viral diseases, such as Newcastle disease, bovine leukemia, AIDS, influenza, measles, rubella, hepatitis B, hepatitis C and Ebola fever; parasitic infestations such as malaria or the disease provoked by *Trypanosoma cruzi*; bacterial infections such as

30

provoked by *Mycobacterium tuberculosis*, by *Yersinia pseudotuberculosis* or by *Listeria monocytogenes*, conditions leading to the development of cancerous cells or development of neurodegenerative diseases such as Alzheimer's disease or Creutzfeldt-Jakob disease (including the new variant).

5

The uses and methods according to the invention are particularly suited for the treatment & prevention of viral diseases especially Newcastle disease, bovine leukemia, Aids, influenza, measles, rubella, hepatitis B, hepatitis C and Ebola fever.

10

As the nature of the effect exhibited by the compounds of formula I is thought to be physical and/or mechanical it has the advantage that it is likely to be non-specific with respect to particular diseases and also less likely to be prone to common drug-resistance and/or drug-interaction phenomena. The preferred compounds of formula I for use in accordance with the present invention are those wherein R², R³ and R⁴ are hydrogen and R¹ is hydrogen or straight chain alkyl of 1-4 carbon atoms.

15

Particularly preferred compounds for use in accordance with the present invention are piracetam, levetiracetam and (R)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide.

20

The term "pharmaceutically acceptable salt" as used herein means addition salts with pharmaceutically acceptable non-toxic organic and inorganic acids, such as acetic, citric, maleic, succinic, ascorbic, hydrochloric, hydrobromic, sulfuric, and phosphoric acids and the like.

25

The term "isomer" as used herein means, when the molecule has a center of asymmetry, the levorotatory and the dextrorotatory enantiomers thereof, more precisely, it means that the said compound comprises at least 90%, preferably at least 95%, by weight of the said individual (either dextro- or levorotatory) optical isomer and at most 10%, preferably at most 5% by weight of the other individual (respectively levo- or dextrorotatory) optical isomer. Each individual optical isomer may be obtained by conventional means, i.e., resolution from the corresponding racemic mixture or asymmetric synthesis.

30

35

The term "fusion peptide" as used herein has the meaning understood in the art namely a short segment of no more than 40 amino acids in length of relatively hydrophobic/hydrophilic residues found in a protein, commonly in a membrane

anchored or interacting polypeptide chain and involved in destabilising cell membranes.

The term "tilted insertion" means insertion into the membrane of the cell
5 across the water/lipid (hydrophilic/hydrophobic) interface at an oblique angle usually between 25° and 75°, particularly 45° and 65°, especially 50° and 60° between to the plane of the cell membrane containing the interface.

Determining whether a particular disease or condition is mediated by or results
10 from the tilted invention of fusion peptides into cell membranes can be determined for example using the methodologies described and reviewed in Brasseur 1991 and Peuvot 1999 referred to above, the content of each of which in this respect is incorporated herein by reference. Once this determination has been made
conventional *in vivo* and *in vitro* testing will establish effectiveness of compounds.
15 Additionally, the likely suitability of a particular compound for interaction with a particular peptide to affect the tilted insertion of fusion peptide can be determined for example in accordance with Peuvot 1995 referred to above and incorporated herein by reference

20 For implementing the method of treatment and use according to the invention, a therapeutically effective amount of a compound of formula I in racemic or isomeric form, or a pharmaceutically acceptable salt thereof should be administered to the patient. An effective amount can be readily determined by the use of conventional techniques and by observing results obtained under analogous circumstances. In
25 determining the effective amount, a number of factors are considered including, but not limited to: the species of patient; his/her body weight, age, and general health; the specific disease to be treated or prevented; the degree of or involvement or the severity of the disease; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the
30 preparation administered; the dose regimen selected; and the use of concomitant medication.

As stated above, in accordance with the present invention the compounds of
formula I in racemic or isomeric form, or as pharmaceutically acceptable salts thereof
35 may be used to manage diseases resulting from the tilted insertion of fusion peptides into cell membranes. This can be done by preventing onset of the disease or by treating it in its acute or chronic form.

For the preventative treatment, the daily dosage can be low, however intake of the drug has to start as early as possible (CITIUS) to prevent the appearance of the disease.

5

Compliance has to be strictly maintained, as long as the threat of the disease lasts. Any missing of drug intake will allow fusion peptides of pathological proteins to insert obliquely into the membranes of the uninfected cells, subsequently leading to the appearance of the clinical stage of the disease, since the synthesis of fusion peptides by infected cells, not stopped by the drug, will continue.

10

For treatment of the acute and chronic stages of the disease, the daily dosage should be higher (ALTIUS). Drug intake has to start as early as possible (CITIUS), once diagnosis has been made, to decrease evolution of the disease, to arrest it, and if possible to eradicate it as could be the case for some diseases such as viral diseases.

15

This favorable effect may be achieved by the efficacy of the compounds according to the invention, as monotherapy, or as add-on therapy to the most efficient products available for the particular disease [for example existing tritherapy / quadritherapy in the case of AIDS (FORTIUS)] in addition to the efficacy of the immune system if still active.

20

Drug intake has to be strictly maintained for as long as clinical and biological examination of the patient shows continued existence of the acute or chronic stage of the disease.

25

Any missing of drug intake will allow fusion peptides of pathological proteins to insert obliquely into the membranes of the uninfected cells. This in turn will lead to the maintenance of the acute clinical stage of the disease eventually allowing the passage to the chronic stage or the maintenance of a pre-existing chronic stage since the synthesis of fusion peptides by infected cells, not stopped by the drug, will continue.

30

For administration in accordance with the present invention a compound of formula I in racemic or isomeric form, or a pharmaceutically acceptable salt thereof may be got up in the form of pharmaceutical compositions which may be administered by any conventional means.

35

Pharmaceutical compositions intended for oral administration may be solid or liquid, for example, in the form of tablets, pills, dragees, gelatin capsules, sublingual formulations, solutions, syrups, and the like.

5

For this purpose, the active compounds can be mixed with an inert diluent or a pharmaceutically acceptable non-toxic carrier, such as for example starch or lactose. Optionally, these pharmaceutical compositions can also contain a binder such as microcrystalline cellulose, gum tragacanth or gelatin, a disintegrating agent such as
10 alginic acid, a lubricant such as magnesium stearate, a glidant such as colloidal silicon dioxide, a sweetening agent such as sucrose or saccharin, a coloring agent or a flavoring agent such as peppermint or methyl salicylate. These compositions also include compositions that allow controlled release of the active substance.

15

Other modes of administration include by injection either intravenously, subcutaneously or intramuscularly.

All such pharmaceutical forms may be prepared according to conventional methods used by pharmacists.

20

The percentage of active compound in the pharmaceutical compositions can vary within very wide concentration limits and depends on a variety of factors such as the sex, age, weight and medical condition of the patient, as well as the mode of administration.

25

In the preferred oral compositions, the dosage unit contains between 250 and 1500mg of active compound. For example in the case of PIRACETAM dosage units containing 400, 800 or 1200mg of active ingredient are appropriate.

30

As regards the daily dosage, this can vary within a wide range of dosage units and it is to be understood that the specific dose will be adapted for particular cases, depending on individual need, at the discretion of the responsible physician. However, for evident pharmacokinetic reasons and due to the mechanism of action of the compounds of the present invention by blocking the fusion of tilted peptides on the
35 membranes of the host cells, it is recommended that the compounds are administered in three divided daily doses.

The following illustrative dosages for piracetam are given for exemplary purposes only and by no means limit the scope of practice of the invention.

As an example, for piracetam, the recommended oral dose schedule for
5 preventative treatment is from 2.4 g to 4.8 g daily.

For acute phase treatment, the recommended oral dose schedule is from 4.8 g daily up to 10.8 g daily depending on the disease and on the severity of the clinical state (for example HBV, HCV, AIDS).

10

For long term treatment of chronic diseases (for example HBV, HCV, AIDS) the recommended oral dose schedule is from 4.8 g daily up to 10.8 g daily.

In severe cases, when patients have already an intravenous access, large doses
15 of up to 12 g daily of piracetam may be administered, also in three divided daily doses.


The following compositions are non-limiting examples of compositions, containing compounds for use according to the invention, suitable for oral administration:

20

| | <u>Composition 1</u> | <u>Composition 2</u> |
|----|-------------------------|-------------------------|
| | XX mg piracetam | XX mg levetiracetam |
| | 200 mg lactose | 400 mg lactose |
| 25 | 1 mg magnesium stearate | 5 mg magnesium stearate |

The invention therefore additionally concerns the use of a compound of formula I, in
30 racemic or isomeric form, or a pharmaceutically acceptable salt thereof,

35



wherein

- R represents hydrogen or hydroxy;
- R^1 and R^2 represent independently hydrogen or an alkyl group of 1-4 carbon atoms; and
- R^3 and R^4 represent independently hydrogen, an alkyl group of 1-4 carbon atoms or $-(CH_2)_n - NR^5R^6$ wherein n is 1, 2 or 3 and R^5 and R^6 represent independently hydrogen or an alkyl group of 1-4 carbon atoms;

for the preparation of a medicament to prevent and treat viral disease. A further aspect of the invention concerns a method of treating or preventing viral disease which comprises administering to a patient needing such treatment or prevention an effective amount of a compound of formula I as described herein.

Particular viral diseases susceptible to such prevention & treatment include Newcastle disease, bovine leukemia, HIV, AIDS, influenza, measles, rubella, hepatitis B, hepatitis C, ebola fever.

The invention is further defined by reference to the following examples describing the efficiency of methods of treatment and prevention according to the present invention.

EXAMPLE 1. Effect of piracetam on patients exhibiting acute viral hepatitis.

Study design

110 patients with acute hepatitis, hospitalised from the first or the second week of icterus, were included in the study. All patients were assigned to rest, and received diet and vitamins.

A first group received piracetam at a daily dose of 2.4 g (3 x 0.8 g/day), a second group received no piracetam and acted as control group. The main parameters were serum bilirubine and transaminases, measured once a week during the whole icterus period.

Inclusion criteria were bilirubine (>3.0 mg/daily) ($N < 0.3$) and transaminases (>400 U) ($N < 40$).

The criteria for a positive response were bilirubine <1.5 mg/dl and transaminases <100 U.

5 Results

Clinical tolerance was excellent.

10 The evolution in serum bilirubine levels was very highly significantly reduced (p < 0.0003) for the piracetam group when compared to the control group. This positive evolution was especially observed for patients receiving piracetam from the first week of icterus (time effect) while bulirubine levels were not significantly reduced in patients receiving piracetam from the second week of icterus.

15 The evolution in serum transaminases was also favourable, although non-significant, in patients receiving piracetam. Again, this effect appeared more pronounced for patients receiving piracetam from the first week of icterus suggesting a time-effect relationship.

20 Except for 6 patients out of 49, the icterus phase for the piracetam group was reduced by 50% when compared to the control group.

These results indicate a potential therapeutic effect of piracetam in acute hepatitis.

25

EXAMPLE 2. Effect of piracetam on patients exhibiting chronic C virus hepatitis.

Study design

30 6 patients with chronic transfusion associated hepatitis C virus (HCV) received 6 months therapy with piracetam at a daily dose of 10.8 g (3 x 3.6 g/d) with no other treatment associated. This was followed by a 3 months period of no treatment.

35 All patients, interferon non-responders, had chronic hepatitis from 6 to 19 years. The main criterion of efficacy was serum viral load (HCV-RNA) performed by polymerase chain reaction (PCR) at 0, 3, 6 and 9 months.

These patients had manifested a gradual rise in their HCV-RNA. Thus, the criteria for no response was defined as no change in the increase of HCV-RNA, a positive response as a *status quo* of serum HVC-RNA and a significant response as a decrease of at least half a log of HCV-RNA.

5

Results

10

Clinical tolerance was excellent.

Two patients had an increase inferior to 10%. Four patients had a decrease, which was significant ($\Delta < 0.6$ log) in the patient who was the most recently infected (6 years) suggesting potential therapeutic effect at piracetam in chronic hepatitis C.

15

EXAMPLE 3. *In vitro* inhibitory effect of piracetam on the formation of syncytia induced by fusion of HIV infected cells with uninfected neighbouring cells.

20

HIV has the property on cultured cells to provoke the formation of syncytia by fusion of infected cells with uninfected neighboring cells, when the virus ends its replication.

25

Virus have become remarkably opportunistic in exploring whatever complicated shapes they may find on the host cell surface as binding receptors (e.g. CD4, CXCR4, CCR5, CKR-5, CKR-3).

30

This study therefore investigated the ability of piracetam to inhibit the formation of syncytia, while interfering with CD4, the primary binding receptor of HIV. For this purpose, two cultures of cells were used, A-201 cells devoid of CD4 receptors and SUP-T1 cells presenting CD4 receptors.

35

Piracetam, accordingly to the doses used, inhibited the process leading to the formation of syncytia, whether or not the cell presents the CD4 binding receptor, confirming its aspecific action. This *in vitro* effect on the membrane is very clear.

Based upon this result, the ability of piracetam to inhibit the fusion of large unilamellar vesicles (LUV), made of the main 4 PL of the envelope of the virus, and provoked by the titled peptide of HIV-wt (wild type)(16 AA) and of SIV-wt (12AA) was investigated.

5

At the doses tested, piracetam inhibits the fusion of LUV in the presence of these two tilted peptides.

10

EXAMPLE 4. Levetiracetam and (R)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide.

The same in vitro study as in Example 1 was used to investigate two analogues (levetiracetam and (R)-(-)-alpha-ethyl-2-oxo-1-pyrrolidine acetamide) in comparison with piracetam.

15

At the doses tested, these two analogues have also shown a very clear inhibitory effect on the fusion process induced on LUV by the viral tilted peptide.

20 EXAMPLE 5. *In vitro* inhibitory effect of piracetam on the fusion process induced by the two Alzheimer's Beta-amyloid tilted peptides on membrane models :

25

Four fundamental studies using different tools such as conformational analysis, biophysical methods, NMR and two-hybrid assay were carried out.

They showed the efficacy of piracetam to inhibit the fusion process induced by the two Alzheimer's β -amyloid tilted peptides (29-40 and 29-42) on membrane models.

30

Results reported that, whatever the amyloid peptide is, preincubation in vitro of piracetam before the addition of each tilted peptide inhibits almost completely the fusion process induced by the two amyloid peptides.


35

Furthermore, it is interesting to note that , whatever the dose of piracetam is , when piracetam is introduced after incubation of the amyloid peptide with liposomes , piracetam is not able to inhibit the fusion process already in progress .

Two-hybrid assay showed that this effect is neither located in the cytoplasm nor in the nucleus of the cell. This inhibitory effect of piracetam on the fusion process induced by the two amyloid tilted peptides seems to be strictly located at the level of the membrane of the cell.

CLAIMS

1. The use of a compound of formula I, in racemic or isomeric form, or a pharmaceutically acceptable salt thereof,



wherein


- R represents hydrogen or hydroxy;
- R¹ and R² represent independently hydrogen or an alkyl group of 1-4 carbon atoms; and
- R³ and R⁴ represent independently hydrogen, an alkyl group of 1-4 carbon atoms or $-(CH_2)_n - NR^5R^6$ wherein n is 1, 2 or 3 and R⁵ and R⁶ represent independently hydrogen or an alkyl group of 1-4 carbon atoms;

for the preparation of a medicament to prevent and treat diseases resulting from or mediated by the tilted insertion of fusion peptides into cell membranes.

2. The use according to claim 1 wherein the disease is a viral disease.

3. The use according to claim 2 wherein the viral disease is selected from Newcastle disease, bovine leukemia, HIV, AIDS, influenza, measles, rubella, hepatitis B, hepatitis C, ebola fever.

4. The use of a compound of formula I, in racemic or isomeric form, or a pharmaceutically acceptable salt thereof,



wherein

- R represents hydrogen or hydroxy;
- R¹ and R² represent independently hydrogen or an alkyl group of 1-4 carbon atoms; and
- R³ and R⁴ represent independently hydrogen, an alkyl group of 1-4 carbon atoms or $-(CH_2)_n - NR^5R^6$ wherein n is 1, 2 or 3 and R⁵ and R⁶ represent independently hydrogen or an alkyl group of 1-4 carbon atoms;

for the preparation of a medicament to prevent and treat viral disease.

10

5. The use according to claim 4 wherein the viral disease is selected from Newcastle disease, bovine leukemia, HIV, AIDS, influenza, measles, rubella, hepatitis B, hepatitis C, ebola fever.

15

6. The use according to any one of claims 1 to 5 wherein R¹, R², R³ and R⁴ are hydrogen.

7. The use according to any one of claims 1 to 5 wherein R¹ is an ethyl, and R², R³ and R⁴ are hydrogen.

20

8. The use according to claim 7 wherein the compound is in the form of its (R) isomer.

25

9. The use according to any one of claims 1 to 8 wherein the compound of formula I is in the form of a pharmaceutically acceptable salt.

30

10. A method of treating and preventing conditions resulting from the tilted insertion of fusion peptides which comprises administering to a patient needing such treatment or prevention an effective amount of a compound of formula I as described in claim 1.

11. A method according to claim 10 wherein the condition is a viral disease.

35

12. A method according to claim 11 wherein the viral disease is selected from Newcastle disease, bovine leukemia, HIV, AIDS, influenza, measles, rubella, hepatitis B, hepatitis C, ebola fever.

13. A method of treating or preventing viral disease which comprises administering to a patient needing such treatment or prevention an effective amount of a compound of formula I as described in claim 1.
- 5 14. A method according to claim 13 wherein the viral disease is selected from Newcastle disease, bovine leukemia, HIV, AIDS, influenza, measles, rubella, hepatitis B, hepatitis C, ebola fever.
- 10 15. A method according to any one of claims 10 to 14 wherein R^1 , R^2 , R^3 and R^4 are hydrogen.
16. The use according to any one of claims 10 to 14 wherein R^1 is an ethyl, and R^2 , R^3 and R^4 are hydrogen.
- 15 17. The use according to claim 16 wherein the compound is in the form of its (R) isomer.
18. The use according to any one of claims 10 to 17 wherein the compound of formula I is in the form of a pharmaceutically acceptable salt.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/03106

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/4015 A61P31/04 A61P31/12 A61P33/00 A61P31/16
 A61P31/18 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, BIOSIS, EPO-Internal, WPI Data, PAJ, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | NALBANDIAN R M ET AL: "Erythrocyte - endothelial cell adherence in sickle cell disease, diabetes mellitus, and falciparum malaria: adverse effects reversed with piracetam." MEDICAL HYPOTHESES, (1982 FEB) 8 (2) 155-62., XP001027520 page 158, paragraph 3 | 1-18 |
| X | ROSSINI P M ET AL: "Jakob- Creutzfeldt disease: analysis of EEG and evoked potential under basal conditions and neuroactive drugs." EUROPEAN NEUROLOGY, (1979) 18 (4) 269-79., XP002188464 abstract | 1-18 |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

8 July 2002

Date of mailing of the international search report

15/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Herrera, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/03106

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | US 4 145 347 A (L ITALIEN YVON J ET AL) 20 March 1979 (1979-03-20) cited in the application column 3, line 3-11; claims 1-12 --- | 1-18 |
| X | EP 0 165 919 A (UCB SA) 27 December 1985 (1985-12-27) cited in the application page 11, line 6-24 --- | 1-18 |
| A | CEREHINO J J ET AL: "Levetiracetam for partial seizures: Results of a double-blind, randomized clinical trial." NEUROLOGY, vol. 55, no. 2, 25 July 2000 (2000-07-25), pages 236-242, XP002188465 ISSN: 0028-3878 abstract ----- | 1-18 |

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 10-18 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 02/03106

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/03106

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|----------------------------|
| US 4145347 | A | 20-03-1979 | AU 514354 B2 05-02-1981 |
| | | | AU 3359878 A 30-08-1979 |
| | | | BE 864269 A1 16-06-1978 |
| | | | CA 1073457 A1 11-03-1980 |
| | | | DE 2808067 A1 07-09-1978 |
| | | | DK 85478 A ,B, 04-09-1978 |
| | | | ES 467288 A1 16-10-1978 |
| | | | FR 2382441 A1 29-09-1978 |
| | | | GB 1588082 A 15-04-1981 |
| | | | HK 59683 A 02-12-1983 |
| | | | JP 1374717 C 22-04-1987 |
| | | | JP 53108966 A 22-09-1978 |
| | | | JP 61041908 B 18-09-1986 |
| | | | MY 26984 A 31-12-1984 |
| | | | SG 38583 G 27-07-1984 |
| EP 0165919 | A | 27-12-1985 | AT 45348 T 15-08-1989 |
| | | | AU 574175 B2 30-06-1988 |
| | | | AU 4252985 A 21-11-1985 |
| | | | BG 50272 A3 15-06-1992 |
| | | | BG 60030 A3 15-07-1993 |
| | | | CA 1237138 A1 24-05-1988 |
| | | | CY 1568 A 20-12-1991 |
| | | | DE 3572168 D1 14-09-1989 |
| | | | DK 212885 A ,B, 16-11-1985 |
| | | | EP 0165919 A1 27-12-1985 |
| | | | ES 543125 D0 16-02-1987 |
| | | | ES 8703419 A1 01-05-1987 |
| | | | ES 551366 D0 01-06-1987 |
| | | | ES 8706114 A1 16-08-1987 |
| | | | FI 851876 A ,B, 16-11-1985 |
| | | | GR 851156 A1 25-11-1986 |
| | | | HK 62692 A 28-08-1992 |
| | | | IE 58393 B 08-09-1993 |
| | | | IL 75180 A 31-05-1988 |
| | | | JP 60255764 A 17-12-1985 |
| | | | KR 9203818 B1 15-05-1992 |
| | | | NO 851934 A ,B, 18-11-1985 |
| | | | PL 253373 A1 06-05-1986 |
| | | | PL 257386 A1 07-10-1986 |
| | | | PT 80461 A ,B 01-06-1985 |
| | | | SG 80190 G 23-11-1990 |
| | | | SU 1417799 A3 15-08-1988 |
| | | | SU 1320207 A1 30-06-1987 |
| | | | SU 1428194 A3 30-09-1988 |
| | | | US 4837224 A 06-06-1989 |
| | | | US 4696942 A 29-09-1987 |
| | | | ZA 8503636 A 24-12-1985 |

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.